129.11
-0.29 (-0.22%)
| Previous Close | 129.40 |
| Open | 129.94 |
| Volume | 387,387 |
| Avg. Volume (3M) | 1,367,250 |
| Market Cap | 12,777,474,048 |
| Price / Earnings (TTM) | 43.91 |
| Price / Earnings (Forward) | 24.57 |
| Price / Sales | 5.43 |
| Price / Book | 4.94 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.09% |
| % Held by Institutions | 98.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 31 Mar 2025 | 1,489,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 185.00 (Evercore ISI Group, 43.29%) | Buy |
| Median | 154.00 (19.28%) | |
| Low | 115.00 (BMO Capital, -10.93%) | Hold |
| Average | 153.67 (19.02%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 116.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 02 Jun 2025 | 145.00 (12.31%) | Buy | 124.56 |
| 06 May 2025 | 145.00 (12.31%) | Buy | 118.92 | |
| BMO Capital | 06 May 2025 | 115.00 (-10.93%) | Hold | 118.92 |
| Canaccord Genuity | 06 May 2025 | 160.00 (23.93%) | Buy | 118.92 |
| 28 Apr 2025 | 158.00 (22.38%) | Buy | 106.46 | |
| Guggenheim | 06 May 2025 | 165.00 (27.80%) | Buy | 118.92 |
| Needham | 06 May 2025 | 139.00 (7.66%) | Buy | 118.92 |
| 15 Apr 2025 | 138.00 (6.89%) | Buy | 96.16 | |
| Piper Sandler | 06 May 2025 | 154.00 (19.28%) | Buy | 118.92 |
| UBS | 06 May 2025 | 152.00 (17.73%) | Buy | 118.92 |
| Evercore ISI Group | 24 Apr 2025 | 185.00 (43.29%) | Buy | 105.76 |
| HC Wainwright & Co. | 22 Apr 2025 | 168.00 (30.12%) | Buy | 101.74 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |